FDA Approves First-Ever Drug for Agitation Associated with Alzheimer’s Dementia By Mark TerryMay 11, 2023 The U.S. Food and Drug Administration approved the supplemental New Drug Application (sNDA) for Rexulti [….]
Temple Research Suggests FDA-Approved Drugs Might Prevent Alzheimer’s
Published on :Temple Research Suggests FDA-Approved Drugs Might Prevent Alzheimer’s By Mark TerryMay 3, 2023 The FDA approved Biogen’s Aduhelm (aducanumab) to treat early Alzheimer’s in June of 2021. Then, in 2022, [….]
Annovis Bio: Embracing Novel Approaches to Parkinson’s and Alzheimer’s Diseases
Published on :Annovis Bio: Embracing Novel Approaches to Parkinson’s and Alzheimer’s Diseases By Mark Terry April 21, 2023 In a recent conference call and announcement, Berwyn, Penn.-based Annovis Bio discussed its progress [….]
NeuroNascent Takes New Path for Alzheimer’s Treatment
Published on :Alzheimer’s disease has been one of the toughest disorders for drugmakers to tackle, with multiple trial failures year after year. Companies have exhausted resources as they examined different pathways in what have mostly been futile attempts to develop a therapeutic to halt or delay the onset of this devastating neurodegenerative disease.
Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders
Published on :Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders Several Maryland Biotech Firms Are Blazing New Trails in Gene Therapy, Drugs and Diagnostics for Neurological [….]
Germantown, MD-based Neuraly & Theraly Fibrosis Advance Clinical Parkinson’s and Alzheimer’s Candidates with $137.1M in Series B Financing Raised by Parent Company D&D Pharmatech
Published on :Neuraly Theraly Fibrosis raise $137.1M in Series B from Korean Parent Company DD Pharmatech
3 Promising Maryland Biotechs that are Targeting Neurological Disorders
Published on :3 Promising Maryland Biotechs that are Targeting Neurological Disorders BrainScope, AgeneBio and Neuraly February 13, 2019 Neurological disorders are diseases of the central nervous system such as Alzheimer’s and Parkinson’s. [….]